Tenofovir Disoproxil Fumarate Tablet

Adult dose

Adults: For the treatment of HIV-1 or chronic hepatitis B, take 1 tablet once daily (equivalent to 245mg of tenofovir disoproxil). It may be taken with or without food. The optimal duration of treatment for chronic hepatitis B is unknown. Patients with renal impairment For patients with a baseline creatinine clearance of <50mL/min, adjust the dosing interval of this medicine with reference to Table 1. Creatinine clearance (mL/min)a ≥50: Every 24 hours Creatinine clearance (mL/min)a 30-49: Every 48 hours Creatinine clearance (mL/min)a 10-29: Every 72-96 hours Patients on hemodialysis: Every 7 days or approximately 12 hours after dialysisb No adjustment of the dosing interval is necessary in patients with mild renal impairment (creatinine clearance 50-80mL/min). a. Calculated using ideal (lean body) weight. b. Administer once weekly, assuming hemodialysis sessions of approximately 4 hours each, 3 times per week. This medicine should be administered after dialysis is completed. The pharmacokinetics of tenofovir have not been evaluated in patients with creatinine clearance below 10mL/min who are not receiving hemodialysis; therefore, no dosing recommendations are available for these patients.

Child dose

Pediatric patients 12 years and older (35kg or more): For the treatment of HIV-1 or chronic hepatitis B, take 1 tablet once daily (equivalent to 245mg of tenofovir disoproxil). It may be taken with or without food. Pediatric patients with chronic hepatitis B weighing less than 35kg: Safety and efficacy have not been established. Pediatric patients with renal impairment: No data are available to recommend a dose.

This medication can severely worsen hepatitis if treatment is stopped, so the liver condition must be monitored closely under medical supervision even after discontinuing treatment. Patients who are allergic to any of the ingredients in this drug or have certain genetic lactose-related disorders should not use it. This drug can affect kidney function, so patients with kidney disease or impaired kidney function must consult their physician before taking it and should have regular kidney function tests during treatment. Interactions may occur when taken with certain other medications, so if you are taking other medications, be sure to inform and consult your doctor or pharmacist. This drug can impact bone health, so patients at risk of osteoporosis or fractures should regularly undergo bone density tests and may need to take calcium and vitamin D supplements. Women who are pregnant or planning to become pregnant must consult their physician about the use of this drug, and breastfeeding should be avoided while on this medication. Pediatric patients under 12 years of age or weighing less than 35 kg have restricted use as safety and efficacy have not been sufficiently established. Elderly patients should use caution as there may be decreased liver, kidney, and heart function, and dosage adjustments or further testing may be necessary. In case of overdose, medical attention should be sought immediately, and this drug can be partially removed through hemodialysis. This medication should be stored in a tightly closed container away from air and moisture, at room temperature between 1 to 30 degrees Celsius, to maintain its efficacy.

• worsening of hepatitis
• acute renal failure
• Fanconi syndrome
• hypophosphatemia
• bone pain
• limb pain
• fractures
• muscle pain
• proximal tubular dysfunction
• rash

This drug should be stored in a tightly closed container to protect from air or moisture, preferably at room temperature between 1 to 30 degrees Celsius. By storing it this way, the effectiveness of the drug can be maintained for a long time.

Appearance

Pale blue almond-shaped film-coated tablet

Package unit

30 tablets/bottle